BridgeMD
The Dan-DAPT trial
EU CTIS ID: 2022-500125-32-00
What this study is testing
This trial aims to improve existing dual antiplatelet therapy (DAPT) routines by assessing if patients with myocardial infarction, who are at high bleeding risk, can be safely allocated to an individualized, de-escalated DAPT strategy with clopidogrel using Cytochrome P2C19-genotyping and shorter duration of DAPT to reduce bleedings without increasing the risk of ischemic events.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Inclusion criteria: 1. MI caused by atherothrombotic CAD (Type 1 MI) according to “The Fourth Universal Definition of MI”, which has been treated with PCI with contemporary drug-eluting stents. This definition of type 1 MI requires the detection of a rise and/or fall of cardiac troponin values with at least one value >99th percentile and at least one of the following criteria assessed by the treating physician: • symptoms indicating acute myocardial ischemia • new ischemic changes on the electrocardiogram • development of pathological Q-waves • imaging evidence of new loss of viable myocardium or new regional wall motion abnormality in a pattern consistent with an ischemic etiology • visible coronary thrombus by angiography 2. PRECISE-DAPT score ≥25 3. Age ≥18 years
You likely can't join if
- 1. Contraindications including allergies to ASA or P2Y12 inhibitors 2. Indication for oral anticoagulation 3. Previous stent thrombosis 4. Life expectancy <1 year 5. Resuscitated cardiac arrest with Glasgow Coma Scale <8 and/or need of intubation 6. Prior intracranial hemorrhage 7. Active bleeding (BARC ≥2) at randomization 8. Women who are pregnant, have given birth recently (within the past 90 days), are lactating, or are fertile without contraception 9. Hypertensive crisis (systolic blood pressure >180 mmHg and/or diastolic blood pressure >120 mmHg) 10. Unable to understand and follow study-related instructions or to comply with study protocol
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.